PAR. SP, page-1134

My thoughts entirely. Whatever we might get in return, the FDA are effectively handing us a gigantic invoice. The only questions are a) how gigantic? and b) how do we pay?

If it’s solely via cap raises, then we must be dangerously close to having to conclude that nobody is interested in this for a reason we retailers just cannot see (e.g a problem with the supply agreement, or IP, or whatever it might be. If that’s the case, the SOI will have to multiply for us to see trials through, and that’s more or less a death knell for many retailers hopes of PARs all-time-high share prices being in the future rather than the rear view mirror.

There has to be some plan in place for financing, a deal or something, anything, hot on the heels of an FDA amber or green light. If there isn’t, then it could get really ugly really quickly.